Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 15;9(1):e2017026.
doi: 10.4084/MJHID.2017.026. eCollection 2017.

Assessment of Obesity and Hepatic Late Adverse Effects in the Egyptian Survivors of Pediatric Acute Lymphoblastic Leukemia: a Single Center Study

Farida H El-Rashedy  1 , Mahmoud A El-Hawy  1 , Sally M El Hefnawy  2 , Mona M Mohammed  3
Affiliations

Assessment of Obesity and Hepatic Late Adverse Effects in the Egyptian Survivors of Pediatric Acute Lymphoblastic Leukemia: a Single Center Study

Farida H El-Rashedy et al. Mediterr J Hematol Infect Dis. .

Abstract

Background: Childhood acute lymphoblastic leukemia (ALL) with current cure rates reaching 80% emphasizes the necessity to determine treatment-related long-term effects. The aim of this study is to estimate the prevalence of overweight, obesity, and hepatic late adverse effects in a cohort of ALL survivors treated at the Hematology and Oncology Unit, Pediatrics Department, Menoufia University, Egypt.

Methods: In this case-control study, height, weight, and body mass index (BMI) were assessed for 35 pediatric ALL survivors and 35 healthy children. These parameters were plotted on the growth and WHO standard deviation charts for both males and females. Overweight and obesity were defined by BMI > 85th and 95th percentile respectively. Laboratory investigations were done in the form of iron profile, liver enzymes, total and direct bilirubin levels, serum urea &creatinine and detection of hepatitis C virus antibodies by ELISA.

Results: The weight and BMI were significantly greater in the survivors than controls (P value =0.002 and 0.039 respectively). ALT, total & direct bilirubin, serum ferritin and transferrin saturation were considerably higher in the survivors than the controls (P value = 0.03, 0.036, 0.044, 0.006 and 0.03 respectively). Ten (28.6%) of survivors had hepatitis C antibodies with none (0%) of controls (P value =0.02).

Conclusions: Pediatric ALL survivors are at increased risk of overweight/obesity, hepatic dysfunction in the form of elevated liver enzymes, bilirubin levels, and C viral hepatitis. Screening of those survivors for such complications should be considered.

Keywords: ALL; Liver function; Obesity; Survivors.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors have declared that no competing interests exist.

References

    1. Shalaby R, Ashaat N, El-Wahab N, El-Hamid M, El-Wakeel S. Bcl-2 expression and chromosomal abnormalities in childhood acute lymphoblastic leukemia. Academic Journal of Cancer Research. 2010;3(2):34–43.
    1. Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program. J Cancer Epidemiol. 2014;2014:437971. doi: 10.1155/2014/437971. https://doi.org/10.1155/2014/437971. - DOI - PMC - PubMed
    1. Tantawy AA, El-Rashidy FH, Ragab IA, Ramadan OA, El-Gaafary MM. Outcome of childhood acute Lymphoblastic leukemia in Egyptian children: a challenge for limited health resource countries. Hematology. 2013;18(4):204–210. https://doi.org/10.1179/1607845412Y.0000000061. - DOI - PubMed
    1. Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309:2371–81. https://doi.org/10.1001/jama.2013.6296. - DOI - PMC - PubMed
    1. Zhang F, Liu S, Chung M, Kelly M. Growth patterns during and after treatment in patients with pediatric ALL: A meta-analysis. Pediatr Blood Cancer. 2015;62(8):1452–1460. https://doi.org/10.1002/pbc.25519. - DOI - PMC - PubMed